<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309163</url>
  </required_header>
  <id_info>
    <org_study_id>ETPPD Trail</org_study_id>
    <nct_id>NCT03309163</nct_id>
  </id_info>
  <brief_title>Effect of Tramadol in Prevention of Postpartum Depression</brief_title>
  <acronym>ETPPD</acronym>
  <official_title>Effect of Tramadol in Prevention of Postpartum Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of postpartum depression in Europe and the United States is about 10%, while in&#xD;
      China the incidence rate of 15.7-39.8%. Postpartum depression is one of the most common&#xD;
      diseases of perinatal distress, but the current research of high-quality prevention and&#xD;
      treatment of postpartum depression is still very lack. The study suggests that the risk of&#xD;
      postpartum depression in cesarean delivery is significantly higher than that in vaginal&#xD;
      delivery. Therefore, postpartum depression in cesarean delivery may require more attention&#xD;
      and treatment.Tramadol is a non-opioid central analgesic that relieves common to severe pain,&#xD;
      and tramadol has an inhibitory effect on norepinephrine and serotonin systems and has the&#xD;
      potential to reduce depression and anxiety. Therefore, for the analgesic demand and&#xD;
      antidepressant demand for maternal who undergoing cesarean section, tramadol may be an&#xD;
      optimized and effective analgesic for the prevention and treatment of postpartum depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed according to a prospective, randomized, controlled clinical trial.&#xD;
      Randomized subjects were randomly assigned to different analgesic drug-treated groups&#xD;
      according to the random number induced by SPSS software. All three analgesic treatments were&#xD;
      routinely used for clinical analgesia; Anesthesia, surgery, postoperative treatment are in&#xD;
      accordance with clinical practice. The investigators conducted a postoperative questionnaire&#xD;
      survey and psychological diagnosis for all patients. And blood sample was collected from&#xD;
      patients before and 48 hours after the surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2017</start_date>
  <completion_date type="Actual">August 13, 2019</completion_date>
  <primary_completion_date type="Actual">June 13, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of postpartum depression</measure>
    <time_frame>At 4 weeks after the surgery</time_frame>
    <description>Diagnosed according to DSM-5 diagnostic criteria for postnatal depression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of postpartum depression</measure>
    <time_frame>At 3 months after the surgery</time_frame>
    <description>Diagnosed according to DSM-5 diagnostic criteria for postnatal depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EPDS scores</measure>
    <time_frame>At 4 weeks and 3 months after the surgery</time_frame>
    <description>Measured using Edinburgh Postnatal Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAD-7 scores</measure>
    <time_frame>At 4 weeks and 3 months after the surgery</time_frame>
    <description>Measured using Generalized Anxiety Disorder Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoR-15 scores</measure>
    <time_frame>48 hours after the surgery</time_frame>
    <description>Measured using Quality of recovery 15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>At 6, 12, 24 and 48 hours after the surgery</time_frame>
    <description>Pain VAS at 6, 12, 24 and 48 hours after the surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine and serotonin levels in the blood</measure>
    <time_frame>At 48 hours after the surgery</time_frame>
    <description>Norepinephrine and serotonin concentration in the blood at 48 hours after the surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Early walking time</measure>
    <time_frame>During hospitalization, an average of 36 hours</time_frame>
    <description>The time for patient to independently activity</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital stays</measure>
    <time_frame>During hospitalization, an average of 72 hours</time_frame>
    <description>The time for patient to stay in hospital after the surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Pain intensity</measure>
    <time_frame>At 3 months after the surgery</time_frame>
    <description>Postoperative pain intensity that evaluated by questionnaire at 3 months after the surgery</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1230</enrollment>
  <condition>Caesarean Section</condition>
  <arm_group>
    <arm_group_label>Group T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients receive the patient-controlled intravenous analgesia with Tramadol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients receive the patient-controlled intravenous analgesia with Hydromorphone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients receive the patient-controlled epidural analgesia with Ropivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>Patient-controlled intravenous analgesia with Tramadol</description>
    <arm_group_label>Group T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone</intervention_name>
    <description>Patient-controlled intravenous analgesia with Hydromorphone</description>
    <arm_group_label>Group H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine (Epidural analgesia)</intervention_name>
    <description>Patient-controlled epidural analgesia with Ropivacaine.</description>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20 years old ≤ age ≤ 40 years old;&#xD;
&#xD;
          -  ASA score I-Ⅱ;&#xD;
&#xD;
          -  uncomplicated and singleton full-term pregnancy;&#xD;
&#xD;
          -  voluntarily to receive cesarean section and postoperative controlled analgesia;&#xD;
&#xD;
          -  consent to participate the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with history of mental disorders or psychotropic substances use;&#xD;
&#xD;
          -  with history of neurological diseases such as epilepsy&#xD;
&#xD;
          -  with history of previously known diagnosed depression;&#xD;
&#xD;
          -  with suicidal ideation or history of suicide;&#xD;
&#xD;
          -  with history of drug，alcohol or opioid abuse;&#xD;
&#xD;
          -  with monoamine oxidase (MAO) inhibitor treatment at present or in the past 14 days;&#xD;
&#xD;
          -  participating in other clinical studies&#xD;
&#xD;
          -  with severe heart disease, brain disease, liver disease and kidney disease;&#xD;
&#xD;
          -  be allergic to tramadol or opioids;&#xD;
&#xD;
          -  with any contraindication for combined spinal epidural anesthesia;&#xD;
&#xD;
          -  incapable of communication or cooperation.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Anesthesiology, Xinqiao Hospital, Third Military Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xinqiao Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 28, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Hong Li</investigator_full_name>
    <investigator_title>Director, Department of Anesthesiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression, Postpartum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

